Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sichuan Univ. SOS1 compound 78d
- Development stage
- Unknown
- Lead developer
- Sichuan University
01
Overview
Sichuan Univ. SOS1 compound 78d: sourced facts only. name: "This effort yielded highly potent and selective SOS1 inhibitors, 78b and 78d, which displayed high SOS1 binding affinity, potently disrupted the SOS1-KRASG12C interaction, and inhibited nucleotide exchange in WT and multiple KRAS variants." [PMID:42247371]; target: "This effort yielded highly potent and selective SOS1 inhibitors, 78b and 78d, which displayed high SOS1 binding affinity, potently disrupted the SOS1-KRASG12C interaction, and inhibited nucleotide exchange in WT and multiple KRAS variants." [PMID:42247371]; developer: "Department of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China." [PMID:42247371]
02
Targets
SOS1 (Son of sevenless homolog 1)
Beyond the preview
Go deeper on Sichuan Univ. SOS1 compound 78d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sichuan Univ. SOS1 compound 78d.